Here we report a novel role of SET antagonism in T-ALL and show that combined targeting of tyrosine kinases and activation of PP2A may offer an effective and novel therapeutic strategy for the treatment of NOTCH-dependent and independent T-ALL. The gene discussed is SET; the disease is acute lymphoblastic leukemia.